Mexiletine Hydrochloride
Brand Names: Mexitil
Methodology & AI Transparency ⓘ
Mexiletine Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.
- 2 Real-world patient consensus: Real-world cohort score of 79% across 17 de-identified Mexiletine Hydrochloride entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $11.16 on Cost Plus Drugs to $34.50 walk-in retail (NADAC $0.2570/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Mexiletine Hydrochloride: palpitations (2.2%), nausea (8.8%), headache (7.2%).
Ask our AI Specialists anything about Mexiletine Hydrochloride
Mexiletine Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Mexiletine hydrochloride capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital.
CLINICAL PHARMACOLOGY Mechanism of Action Mexiletine hydrochloride is a local anesthetic, antiarrhythmic agent, structurally similar to lidocaine, but orally active. In animal studies, mexiletine has been shown to be effective in the suppression of induced ventricular arrhythmias, including those induced by glycoside toxicity and coronary artery ligation. Mexiletine, like lidocaine, inhibits the inward sodium current, thus reducing the rate of rise of the action potential, Phase 0. Mexiletine decreased the effective refractory period (ERP) in Purkinje fibers.
Pharmacokinetic profiling of Mexiletine Hydrochloride demonstrates an elimination half-life of Elimination kinetics span 8 to 18 hours per Mexiletine Hydrochloride clinical pharmacology with Consistent 78%–90% gastrointestinal absorption profile for Mexiletine Hydrochloride systemic bioavailability; clearance proceeds via systemic clearance of mexiletine hydrochloride integrates hepatic phase ii conjugation with renal filtration, reaching clinical onset within cmax attained 2–5 hours post-administration of mexiletine hydrochloride.
Titration schedules for Mexiletine Hydrochloride (250 mg/1 Capsule → 200 mg/1 Capsule → 150 mg/1 Capsule → 150mg Capsule → 200mg Capsule) require excluding previous anaphylactoid or exfoliative reaction attributed to mexiletine hydrochloride; clinical scenarios where antiarrhythmic exposure from mexiletine hydrochloride poses unacceptable risk; real-world patient logs highlight nausea (8.8% of reports), headache (7.2% of reports), dizziness (6.2% of reports) alongside a 79.00% Worth-It consensus.
Electrophysiologic additive QTc lengthening warrants caution when Mexiletine Hydrochloride is combined with amiodarone or sotalol.
Verify medication reconciliation lists so Mexiletine Hydrochloride is not inadvertently duplicated with another antiarrhythmic.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Mexiletine Hydrochloride
- Clinical scenarios where antiarrhythmic exposure from Mexiletine Hydrochloride poses unacceptable risk
Logged Side-Effect Incidence (17 Reports)
Mexiletine Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mexiletine Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Mexiletine versus lamotrigine in non-dystrophic myotonias: a randomised, We were unable to conclude that lamotrigine is non-inferior to mexiletine; however, improvements in all outcome measures from baseline were similar between lamotrigine and mexiletine. The Lancet. Neurology • 2024-10-15 • Phase III Randomized Trial | N = 30 | 88/100 | PMID 39304240 ↗ |
Mexiletine Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2570/unit (~$7.71/30u) | Wholesale baseline |
| Mark Cuban Cost Plus Drugs (Mail-Order Generic) | Public Wholesale Price List (NADAC + 15% + pharmacy fee) | $11.16 / mo | Formulary listing ↗ |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $12.83 / mo | View logs ↓ |
Mexiletine Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mexiletine Hydrochloride RxNorm Concept ID | 1362706 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2570 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $11.16 / mo (Cost Plus Drugs) | Mark Cuban Cost Plus Public API |
| Real-World Patient Consensus | 79.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mexiletine Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Mexiletine Hydrochloride integrating DailyMed SPL (2024-04-04), CMS NADAC ($0.2570/unit), and 17 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mexiletine Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.